National Health (Immunisation Program—Designated Vaccines) Amendment Determination (No. 2) 2023 (Cth)

National Health (Immunisation Program—Designated Vaccines) Amendment Determination (No. 2) 2023

I, Professor Paul Kelly, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated               4 October         2023

Professor Paul Kelly

Commonwealth Chief Medical Officer

Contents

1............ Name............................................................................................................................. 1

2............ Commencement............................................................................................................. 1

3............ Authority....................................................................................................................... 1

4............ Schedules...................................................................................................................... 1

Schedule 1—Amendments  2

National Health (Immunisation Program – Designated Vaccines) Determination 2014 (No.1)    2

1  Name

This instrument is the National Health (Immunisation Program—Designated Vaccines) Amendment Determination (No. 2) 2023.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 November 2023.	1 November 2023

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under subsections 9B(2) and (5) of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1)

1  After subsection 7(9)

Insert:

(9A)  For item 210A of Schedule 1, a designated vaccine mentioned in that item may be provided to any of the following persons:

(a)  an Aboriginal or Torres Strait Islander who is at least 5 years of age but less than 65 years of age;

(b)  a person who is at least 5 years of age but less than 65 years of age and who:

(i)  has cardiac disease including cyanotic congenital heart disease, coronary artery disease and congestive heart failure; or

(ii)  has a chronic respiratory condition including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema and severe asthma; or

(iii)  has another chronic illness requiring regular medical follow‑up or hospitalisation in the preceding year, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies and impaired immunity (including drug‑induced immune impairment); or

(iv)  has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or

(v)  has impaired immunity, including HIV infection;

(c)  a person who is at least 5 years of age but less than 11 years of age and is receiving long‑term aspirin therapy;

(d)  a woman who is pregnant.

2  Part 1 of Schedule 1 (table item 108C, column headed “Active ingredient and strength”)

Omit “After reconstitution, each of the following”, substitute “Each 0.5mL dose contains”.

3  Part 2 of Schedule 1 (after table item 210)

Insert:

210A Vaccine Influenza Circumstances Vaccine may be provided in the circumstances set out in subsection 7(9A). Flucelvax Quadri Injection (0.5mL) For children at least 5 years of age but less than 9 years of age, 2 doses at least 1 month apart for the first vaccination and one dose per calendar year after that. For persons at least 9 years of age but less than 65 years of age, one dose per calendar year.

4  Part 2 of Schedule 1 (table item 217A)

Repeal the item, substitute:

217A Vaccine Herpes zoster (shingles) Circumstances Vaccine may be provided to a person who is: (a) at least 65 years of age; or (b) at least 50 years of age and an Aboriginal and/or Torres Strait Islander; or (c) at least 18 years of age and who: (i) has had a haemopoietic stem cell transplantation or is scheduled to receive a haemopoietic stem cell transplantation; or (ii) has had a solid organ transplant or is scheduled to receive a solid organ transplant and is on immunosuppressive therapy; or (iii) has an active haematological malignancy; or (iv) has advanced or untreated HIV with CD4 counts < 250/ µL or a higher CD4 count unable to be established on effective anti‑retroviral therapy. Shingrix Powder and suspension for injection (0.5mL) Recombinant varicella zoster virus glycoprotein E antigen (AS01B Adjuvanted) – 50µg (a) unless paragraph (b) applies, 2 primary doses, with the second dose given 2 to 6 months after the first dose; (b) for persons who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy—2 primary doses can be given 1 to 2 months apart